5HU Stock Overview
A clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Hemogenyx Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.005 |
| 52 Week High | UK£0.052 |
| 52 Week Low | UK£0.0005 |
| Beta | 3.26 |
| 11 Month Change | -47.37% |
| 3 Month Change | -44.44% |
| 1 Year Change | -76.74% |
| 33 Year Change | -64.29% |
| 5 Year Change | n/a |
| Change since IPO | -93.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5HU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -54.5% | -1.1% | 1.1% |
| 1Y | -76.7% | -18.8% | 7.2% |
Return vs Industry: 5HU underperformed the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: 5HU underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 5HU volatility | |
|---|---|
| 5HU Average Weekly Movement | 608.0% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5HU's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5HU's weekly volatility has increased from 310% to 608% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 17 | Vladislav Sandler | hemogenyx.com |
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation.
Hemogenyx Pharmaceuticals Plc Fundamentals Summary
| 5HU fundamental statistics | |
|---|---|
| Market cap | €18.00m |
| Earnings (TTM) | -€6.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs 5HU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5HU income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£5.18m |
| Earnings | -UK£5.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0037 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5HU perform over the long term?
See historical performance and comparison